Novel Antischizophrenia Treatments Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Novel Antischizophrenia Treatments book. This book definitely worth reading, it is an incredibly well-written.
Novel Antischizophrenia Treatments by Mark A. Geyer,Gerhard Gross Pdf
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Author : Mark A. Geyer Publisher : Springer Science & Business Media Page : 456 pages File Size : 53,6 Mb Release : 2012-08-31 Category : Medical ISBN : 9783642257575
Novel Antischizophrenia Treatments by Mark A. Geyer Pdf
This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume will concentrate on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Novel Antischizophrenia Treatments by Mark A. Geyer,Gerhard Gross Pdf
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Current Antipsychotics by Gerhard Gross,Mark A. Geyer Pdf
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
James M. Ritter,Emma Robinson,James Fullerton,Humphrey P. Rang
Author : James M. Ritter,Emma Robinson,James Fullerton,Humphrey P. Rang Publisher : Elsevier Health Sciences Page : 785 pages File Size : 50,5 Mb Release : 2014-12-02 Category : Medical ISBN : 9780702054976
Rang & Dale's Pharmacology by James M. Ritter,Emma Robinson,James Fullerton,Humphrey P. Rang Pdf
For 25 years, Rang and Dale’s Pharmacology has delivered the core basic and clinical science information required by students and healthcare practitioners worldwide. Authors H. P. Rang, J. M. Ritter, R. J. Flower, and G. Henderson have ensured that the 8th Edition of this easy-to-read, comprehensive text continues the tradition of excellence with new coverage of drugs affecting the skin and new components online at studentconsult.com. Consult this title on your favorite e-reader. Get the essential pharmacology information you need from one authoritative source with an outstanding global reputation for excellence. Progress confidently through all relevant aspects of pharmacology, beginning with a molecular understanding of receptors and drug actions through clinical uses of key groups of drugs. Find important content quickly thanks to a color-coded layout that enables easy navigation and cross-referencing. Master difficult concepts with Key Points boxes, Clinical Uses boxes, and full-color illustrations throughout. Stay up to date with new information in the field, including an all-new chapter on drugs that affect the skin. Take advantage of new and unique features online, including 500+ chapter-specific multiple choice questions for immediate self-assessment. eBook version included! For the first time, you can access the entire book online or offline across all devices with the Student Consult eBook!
Rudi A.J.O. Dierckx,Andreas Otte,Erik F. J. de Vries,Aren van Waarde,Iris E. Sommer
Author : Rudi A.J.O. Dierckx,Andreas Otte,Erik F. J. de Vries,Aren van Waarde,Iris E. Sommer Publisher : Springer Nature Page : 1075 pages File Size : 45,7 Mb Release : 2020-12-14 Category : Medical ISBN : 9783030572310
PET and SPECT in Psychiatry by Rudi A.J.O. Dierckx,Andreas Otte,Erik F. J. de Vries,Aren van Waarde,Iris E. Sommer Pdf
This book provides a comprehensive overview of the use of PET and SPECT in the classic psychiatric disorders such as depression, bipolar disorder, anxiety disorders, and schizophrenia. In addition, it discusses the application of these functional neuroimaging techniques in a variety of other conditions, including sleep disorders, eating disorders, autism, and chronic fatigue syndrome. The new edition has been extensively revised and updated to reflect the latest advances and results in nuclear imaging within the field. Most chapters are written jointly by a clinical psychiatrist and a nuclear medicine expert to ensure a multidisciplinary approach. This state of the art compendium will be of value for all who have an interest in the field of neuroscience, from psychiatrists and radiologists/nuclear medicine specialists to interested general practitioners and cognitive psychologists. Companion volumes on the use of PET and SPECT in neurology and for the imaging of neurobiological systems complete a trilogy.
Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment by Prasad, Barre Vijaya Pdf
Although the epidemiology of mental illnesses is innately complex, there have been many strides in the diagnosis and treatment of chronic mental illnesses as more research is being conducted in the field. As more information becomes available, mental health professionals are able to develop more effective plans for caring for their patients. Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment examines emergent research on the identification and epidemiology of various mental illnesses. Featuring information on the prevalence of the disease, psychopharmacological advancements, and strategies for the management of chronic mental illnesses, this book is ideally suited for students, psychiatrists, psychologists, neurologists, social workers, rehabilitation therapists, and other health professionals interested in learning more about shifting practices in the mental health sector.
Applied Pharmaceutical Science and Microbiology by Debarshi Kar Mahapatra,Swati Gokul Talele,A. K. Haghi Pdf
This volume on applied pharmaceutical science and microbiology looks at the latest research on the applications of natural products for drug uses. It focuses on understanding how to apply the principles of novel green chemistry methods in the vital area of pharmaceuticals and covers the important aspects of green microbial technology in the pharmaceutical industry. Chapters include studies on the applications of natural products used in folk and regional medicines, such as for digestive problems, dermatological infections, respiratory diseases, vessel diseases, diarrhea and dysentery, ringworms, boils, fevers (antipyretic), skin and blood diseases, mouth sores, channel discharges, and even cancer. The volume also looks at medical benefit of microbial fermentation for the conservation of nutrients.
Small Molecule Therapeutics for Schizophrenia by Sylvain Celanire,Sonia Poli Pdf
The topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drug ability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine.
Beyond Assessment of Quality of Life in Schizophrenia by A. George Awad,Lakshmi N.P. Voruganti Pdf
This book fills a significant research gap in how to integrate quality of life data into relevant clinical care plans, and to broaden its applicability to pharmacoeconomic studies of antipsychotic medications and health policy decision-making. It also presents an argument for reformulating the concept of health-related quality of life in schizophrenia as a bio-psycho-social construct, which provides an opportunity to better explore the many factors underpinning the concept itself. Internationally renowned experts from different scientific backgrounds and scopes of expertise each make arguments for the need to invigorate quality of life as a concept in schizophrenia, by broadening its usefulness for clinical and research efforts. The book represents an important addition to the extensive contributions of its editors, Dr. A. George Awad and Dr. Lakshmi N.P. Voruganti, to the field of quality of life.
Since its discovery in the 1960s, a vast and wide-ranging body of research has accumulated about the dopaminergic system. Life's Rewards: Linking Dopamine, Incentive Learning, Schizophrenia, and the Mind offers a broad synthesis of our current understanding of this chemical, addressing, amongst others, its intricate relationship with learning and memory, psychopathology, social co-operation, and drug abuse. Aimed at students and researchers in neuroscience and psychology, Life's Rewards: Linking Dopamine, Incentive Learning, Schizophrenia, and the Mind is essential reading for anyone interested in the relationship between dopamine and reward-related incentive learning.
Non-Pharmacological Interventions for Schizophrenia: How Much Can Be Achieved and How? by Christina Andreou,Christina Andreou, Steffen Moritz Pdf
The introduction of antipsychotic agents in the 1950’s substantially improved the treatment of schizophrenia and other psychotic disorders. However, clinical and functional outcomes are still far less than optimal for patients, and have not improved in recent years despite the development of several new antipsychotics. Efficacy rates are further compromised by medication non-adherence, which has been reported to affect more than half of patients. In response to these issues, several non-pharmacological interventions have been developed for the treatment of schizophrenia, such as cognitive behavioral therapy, cognitive remediation, social cognition training and metacognitive approaches. Although these interventions have produced promising results, there is still much controversy regarding their usefulness and applicability in clinical practice. A major impeding factor for their dissemination is possibly a lack of sufficient evidence regarding their specific indications, mechanisms of action, adverse effects, but also practical issues concerning the interpretability of respective clinical studies, such as the choice of outcome variables and control of confounding factors. The present Research Topic includes original research articles and reviews addressing these issues.
Current Antipsychotics by Gerhard Gross,Mark A. Geyer Pdf
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.
